Advanced Filter

Filter by Group

Filter by Market Availability

Clear
Displaying drugs 10026 - 10050 of 12494 in total

Tradipitant

Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis, Chronic Pruritus, and Atopic Dermatitis, among others.
Investigational
Matched Description: … Tradipitant has been used in trials studying the treatment and prevention of Eczema, Pruritus, Gastroparesis …

6-hydroxy-1,6-dihydro purine nucleoside

Experimental

CRA_9785

Experimental

(6S)-2-amino-6-(3'-methoxybiphenyl-3-yl)-3,6-dimethyl-5,6-dihydropyrimidin-4(3H)-one

Experimental

CRA-9334

Experimental

Doramapimod

Doramapimod is a P38 MAP kinase inhibitor.
Investigational

Taribavirin

Investigational

(3R)-3-[(1,2,3,4-tetrahydroisoquinolin-7-yloxy)methyl]-2,3-dihydrothieno[2,3-f][1,4]oxazepin-5-amine

Experimental

Tetrahydrouridine

Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast Neoplasms, Sickle Cell Disease, and Head and Neck Cancer, among others.
Investigational
Matched Description: … Tetrahydrouridine has been used in trials studying the treatment of Neoplasms, Lung Neoplasms, Breast …

bis(molybdopterin)tungsten cofactor

Experimental

(S)-blebbistatin

Experimental

SNS-314

SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. SNS-314 inhibits tumor growth in a variety of preclinical models, and...
Investigational
Matched Description: … SNS-314 is a potent and selective inhibitor of Aurora kinases A, B, and C. ... 314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of ... SNS-314 inhibits tumor growth in a variety of preclinical models, and it is now being tested in single …

Amrubicin

Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January...
Investigational
Matched Description: … Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of ... oncology, which licensed Japanese marketing rights from Dainippon Sumitomo, the original developer of …

1-{5-[2-(thieno[3,2-d]pyrimidin-4-ylamino)ethyl]-1,3-thiazol-2-yl}-3-[3-(trifluoromethyl)phenyl]urea

Experimental

1-(5-{2-[(1-methyl-1H-pyrazolo[4,3-d]pyrimidin-7-yl)amino]ethyl}-1,3-thiazol-2-yl)-3-[3-(trifluoromethyl)phenyl]urea

Experimental

MRX-I

MRX-I has been used in trials studying the treatment of Bacterial Infections.
Investigational
Matched Description: … MRX-I has been used in trials studying the treatment of Bacterial Infections. …

2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine

Experimental

Anacetrapib

Investigational

6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine

Experimental

(5S)-2-{[(1S)-1-(4-Fluorophenyl)ethyl]amino}-5-(2-hydroxy-2-propanyl)-5-methyl-1,3-thiazol-4(5H)-one

Experimental

1-[5-Methyl-2-(trifluoromethyl)furan-3-yl]-3-[5-[2-[[6-(1H-1,2,4-triazol-5-ylamino)pyrimidin-4-yl]amino]ethyl]-1,3-thiazol-2-yl]urea

Experimental

Tricetin

Experimental

CRA_1802

Experimental

CRA_10972

Experimental

CRA_11092

Experimental
Displaying drugs 10026 - 10050 of 12494 in total